Standard

Anticancer activity and tissue distribution of platinum (II) complex with lignin-derived polymer of benzene-poly-carboxylic acids. / Solovyev, Nikolay D.; Fedoros, Elena I.; Drobyshev, Evgenii J.; Ivanenko, Natalya B.; Pigarev, Sergey E.; Tyndyk, Margarita L.; Anisimov, Vladimir N.; Vilpan, Yury A.; Panchenko, Andrey V.

In: Journal of Trace Elements in Medicine and Biology, Vol. 43, 01.09.2017, p. 72-79.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Solovyev, Nikolay D. ; Fedoros, Elena I. ; Drobyshev, Evgenii J. ; Ivanenko, Natalya B. ; Pigarev, Sergey E. ; Tyndyk, Margarita L. ; Anisimov, Vladimir N. ; Vilpan, Yury A. ; Panchenko, Andrey V. / Anticancer activity and tissue distribution of platinum (II) complex with lignin-derived polymer of benzene-poly-carboxylic acids. In: Journal of Trace Elements in Medicine and Biology. 2017 ; Vol. 43. pp. 72-79.

BibTeX

@article{7db48e5ae75f4b8783a2f7cd2346c570,
title = "Anticancer activity and tissue distribution of platinum (II) complex with lignin-derived polymer of benzene-poly-carboxylic acids",
abstract = " Platinum-containing antineoplastic agents with physiologically active ligands seem to be a promising direction in anticancer drug design. PDBA is a novel promising antineoplastic agent, containing polymer ligand of natural origin (international patent WO2013/143549 A1). Polymer ligand of PDBA has a highly functionalised polyphenolic backbone, which exerts its own pharmacological effect via immune modulation and regulation of gene expression. PDBA is a cis-diammineplatinum(II) complex, containing mono-deprotonated benzene-poly-carboxylic acids, derived from lignin, and hydroxyl group as O-donor ligands (approximate bulk formula C 83 H 70 N 2 O 27 Pt). The agent is being evaluated in Phase II controlled clinical trials in metastatic breast cancer patients. In the present study, tissue distribution and tumour growth inhibition effects of PDBA, cisplatin and carboplatin were compared in SHR female mice, bearing inoculated solid Ehrlich carcinoma. The agents were administered subcutaneously every second day for the period of 10 days (5 injections) at 62.5 mg/kg, 3.0 mg/kg and 18.5 mg/kg for PDBA, cisplatin and carboplatin, respectively. Experimental animals were sacrificed on the Days 11, 16 and 23 after the inoculation of the tumour. The doses of all studied drugs were selected to obtain similar antitumour efficacy with ca. 50% growth inhibition of the Ehrlich tumour at the end of the study. The efficacy of a single platinum reactive moiety [cis-diammineplatinum(II)] was shown to be the highest for cisplatin, followed by PDBA and finally carboplatin. However, the toxicity of PDBA was considerably lower than that of carboplatin and especially cisplatin. The drugs were mainly distributed in lungs, kidneys, liver, spleen and tumour tissue. PDBA showed quite high accumulation in the tumour tissue, possibly, owing to the effect of the lignin-derived ligand. ",
keywords = "Antineoplastic, Benzene-poly-carboxylic acids, Breast cancer, Non-clinical studies, Platinum, Tissue distribution, tumour suppression",
author = "Solovyev, {Nikolay D.} and Fedoros, {Elena I.} and Drobyshev, {Evgenii J.} and Ivanenko, {Natalya B.} and Pigarev, {Sergey E.} and Tyndyk, {Margarita L.} and Anisimov, {Vladimir N.} and Vilpan, {Yury A.} and Panchenko, {Andrey V.}",
year = "2017",
month = sep,
day = "1",
doi = "10.1016/j.jtemb.2016.11.009",
language = "English",
volume = "43",
pages = "72--79",
journal = "Journal of Trace Elements in Medicine and Biology",
issn = "0946-672X",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",

}

RIS

TY - JOUR

T1 - Anticancer activity and tissue distribution of platinum (II) complex with lignin-derived polymer of benzene-poly-carboxylic acids

AU - Solovyev, Nikolay D.

AU - Fedoros, Elena I.

AU - Drobyshev, Evgenii J.

AU - Ivanenko, Natalya B.

AU - Pigarev, Sergey E.

AU - Tyndyk, Margarita L.

AU - Anisimov, Vladimir N.

AU - Vilpan, Yury A.

AU - Panchenko, Andrey V.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Platinum-containing antineoplastic agents with physiologically active ligands seem to be a promising direction in anticancer drug design. PDBA is a novel promising antineoplastic agent, containing polymer ligand of natural origin (international patent WO2013/143549 A1). Polymer ligand of PDBA has a highly functionalised polyphenolic backbone, which exerts its own pharmacological effect via immune modulation and regulation of gene expression. PDBA is a cis-diammineplatinum(II) complex, containing mono-deprotonated benzene-poly-carboxylic acids, derived from lignin, and hydroxyl group as O-donor ligands (approximate bulk formula C 83 H 70 N 2 O 27 Pt). The agent is being evaluated in Phase II controlled clinical trials in metastatic breast cancer patients. In the present study, tissue distribution and tumour growth inhibition effects of PDBA, cisplatin and carboplatin were compared in SHR female mice, bearing inoculated solid Ehrlich carcinoma. The agents were administered subcutaneously every second day for the period of 10 days (5 injections) at 62.5 mg/kg, 3.0 mg/kg and 18.5 mg/kg for PDBA, cisplatin and carboplatin, respectively. Experimental animals were sacrificed on the Days 11, 16 and 23 after the inoculation of the tumour. The doses of all studied drugs were selected to obtain similar antitumour efficacy with ca. 50% growth inhibition of the Ehrlich tumour at the end of the study. The efficacy of a single platinum reactive moiety [cis-diammineplatinum(II)] was shown to be the highest for cisplatin, followed by PDBA and finally carboplatin. However, the toxicity of PDBA was considerably lower than that of carboplatin and especially cisplatin. The drugs were mainly distributed in lungs, kidneys, liver, spleen and tumour tissue. PDBA showed quite high accumulation in the tumour tissue, possibly, owing to the effect of the lignin-derived ligand.

AB - Platinum-containing antineoplastic agents with physiologically active ligands seem to be a promising direction in anticancer drug design. PDBA is a novel promising antineoplastic agent, containing polymer ligand of natural origin (international patent WO2013/143549 A1). Polymer ligand of PDBA has a highly functionalised polyphenolic backbone, which exerts its own pharmacological effect via immune modulation and regulation of gene expression. PDBA is a cis-diammineplatinum(II) complex, containing mono-deprotonated benzene-poly-carboxylic acids, derived from lignin, and hydroxyl group as O-donor ligands (approximate bulk formula C 83 H 70 N 2 O 27 Pt). The agent is being evaluated in Phase II controlled clinical trials in metastatic breast cancer patients. In the present study, tissue distribution and tumour growth inhibition effects of PDBA, cisplatin and carboplatin were compared in SHR female mice, bearing inoculated solid Ehrlich carcinoma. The agents were administered subcutaneously every second day for the period of 10 days (5 injections) at 62.5 mg/kg, 3.0 mg/kg and 18.5 mg/kg for PDBA, cisplatin and carboplatin, respectively. Experimental animals were sacrificed on the Days 11, 16 and 23 after the inoculation of the tumour. The doses of all studied drugs were selected to obtain similar antitumour efficacy with ca. 50% growth inhibition of the Ehrlich tumour at the end of the study. The efficacy of a single platinum reactive moiety [cis-diammineplatinum(II)] was shown to be the highest for cisplatin, followed by PDBA and finally carboplatin. However, the toxicity of PDBA was considerably lower than that of carboplatin and especially cisplatin. The drugs were mainly distributed in lungs, kidneys, liver, spleen and tumour tissue. PDBA showed quite high accumulation in the tumour tissue, possibly, owing to the effect of the lignin-derived ligand.

KW - Antineoplastic

KW - Benzene-poly-carboxylic acids

KW - Breast cancer

KW - Non-clinical studies

KW - Platinum

KW - Tissue distribution

KW - tumour suppression

UR - http://www.scopus.com/inward/record.url?scp=85008157499&partnerID=8YFLogxK

U2 - 10.1016/j.jtemb.2016.11.009

DO - 10.1016/j.jtemb.2016.11.009

M3 - Article

C2 - 27986470

VL - 43

SP - 72

EP - 79

JO - Journal of Trace Elements in Medicine and Biology

JF - Journal of Trace Elements in Medicine and Biology

SN - 0946-672X

ER -

ID: 7734536